



Rheumatology Association of Nevada

**RAN 3RD ANNUAL MEETING**

**APRIL 27 - 28, 2018**

Hard Rock Hotel & Casino | Lake Tahoe, Nevada

**PROGRAM BOOK**

# WELCOME



Greetings to all Rheumatology Providers,

Foremost, I'd like to take this opportunity to thank everyone who attended our 2017 RAN Meeting, particularly our sponsors for their support, as well as WJ Weiser & Associates, Inc. for their efforts in organizing the event. For those of you who were not able to make it to last year's conference, we had a well-attended and productive meeting with a robust line-up of presentations on academic topics as well

as practical issues regarding the practice of rheumatology.

Today, it's my pleasure to welcome you to the 3rd Annual Meeting of the Rheumatology Association of Nevada, which promises to be equally substantial. It is again a tribute to the planning committee, WJ Weiser & Associates, Inc., and our generous sponsors. For the first time, the meeting will take place in the Northern Nevada, Lake Tahoe area at the Hard Rock Hotel & Casino in Stateline, NV. Also for the first time, there will be an opportunity to spend more time together in a longer meeting, as it will start on Friday, April 27 with registration at 4:30 p.m. and Welcome Reception from 5:30 p.m. to 7:30 p.m.

On Saturday, April 28, we'll have an outstanding group of speakers lecturing on a variety of topics. Our keynote speaker, Dr. Edward Keystone from the University of Toronto, will give us an update on emerging novel therapies in rheumatoid arthritis and biosimilars.

We'll also have a lecture by Dr. Sudhakar Tumuluri, the president of Northern California Rheumatology Society (NCRS), who will discuss management of psoriatic arthritis. Dr. Lester Mertz from the Mayo Clinic Arizona was invited to review treatment of ANCA-associated vasculitis.

Lastly, like last year, we'll have a couple of our local speakers: Dr. Ellen McBride, a psychiatry specialist from Reno kindly agreed to give a suicide prevention talk, which will be particularly useful for our Nevada Medical License renewal. Dr. Robert Lowe from Juvenile Arthritis & Rheumatology Care & Research Center in Las Vegas offered to update us on periodic fever syndromes and other rare autoinflammatory diseases. In addition to these incredible learning opportunities, the event will offer us a perfect occasion to meet and network. Hopefully, we'll have a chance to review together some of the current issues facing us in Nevada and come to a consensus about how we want to proceed as an advocacy group.

Together with the organizing committee, we welcome you to Lake Tahoe for what we envision to be another informative, stimulating, and productive meeting.

Sincerely,

Ewa Olech, MD  
RAN President

## 2018 BOARD OF DIRECTORS

### OFFICERS

#### **President**

Ewa Olech, MD

#### **Vice President**

G. Timothy Kelly, MD

#### **Secretary**

Susan Knowles, MD

#### **Treasurer**

Christianne Yung, MD

### BOARD MEMBERS

Ruth Chan, DO

Carolyn F. Dennehey, MD

William Kim, MD

Robert Lowe, MD, PhD

### 2018 PROGRAM COMMITTEE

Ewa Olech, MD, Program Chair

G. Timothy Kelly, MD

Susan Knowles, MD

Christianne Yung, MD

### RAN BUSINESS OFFICE

Two Woodfield Lake

1100 E. Woodfield Road,

Suite 350

Schaumburg, IL 60173

#### **Executive Director**

Donna Rostamian, MBA

# TABLE OF CONTENTS



Welcome Message .....	Inside Front Cover
2018 Board of Directors.....	Inside Front Cover
CME Information.....	2
Program.....	3
Faculty Disclosure Report.....	4
Biosketches .....	6
Exhibit Hall Floor Plan .....	8
Industry Symposia .....	10
General Meeting Information .....	10
Thank You to Our Supporters .....	11
Notes .....	12

## DISCLAIMER STATEMENT

Statements, opinions, and results of studies contained in the program are those of the presenters/authors and do not reflect the policy or position of RAN, nor does RAN provide any guarantee as to their accuracy or reliability.

## COPYRIGHT NOTICE

Individuals may print out single copies of slides contained in this publication for personal, non-commercial use without obtaining permission from the author or RAN. Permission from both ARA and the author must be obtained when making multiple copies for personal or educational use, for reproduction for advertising or promotional purposes, for creating new collective works, for resale or for all other uses.

## FILMING/PHOTOGRAPHY STATEMENT

No attendee/visitor at the RAN 3rd Annual Meeting may record, film, tape, photograph, interview, or use any other such media during any presentation, display, or exhibit without the express, advance approval of the RAN Executive Director. This policy applies to all RAN members, non-members, guests, and exhibitors, as well as members of the print, online, or broadcast media.

# CME INFORMATION

## EDUCATIONAL NEEDS

The therapeutic landscape has substantially changed with the introduction of biologics and small molecules selectively targeting pathogenic elements in the synovium of RA patients. The introduction of these novel molecules have come about as a consequence of an improved understanding of the pathogenic processes in RA in concert with advances in biotechnology. The critical pathogenic processes include cellular interactions, i.e. T cell, B cell and T cell/Macrophage which generate antibody and cytokine production in particular TNFi, IL-6 and GM-CSF. A novel strategy of signal transduction inhibition of the JAK/stat pathway leads to a reduction of multiple cytokines, an earlier therapeutic response and possible use of monotherapy. All of these novel agents are further improving the outcomes of RA patients.

While biologics have changed the therapeutic paradigm in RA, they have dramatically increased the health care costs with fewer patients generating a larger share of health expenditures. A number of strategies have been put in place to reduce the costs of these therapies without compromising on health care. The more aggressive and early use of combination conventional DMARDs, particularly with SC high dose Methotrexate, have improved outcomes enough to reduce the need for biologics in many cases. As well, recent studies demonstrating the withdrawal of biologics in early RA or dose reduction in more established RA will contribute to reduced health care costs. Moreover, the introduction of biosimilars has already had a substantial effect on reducing biologic costs. Improved therapeutic algorithms will reduce the time wasted with ineffective therapy. Taken together, the early therapeutic strategies with conventional DMARDs, biologic dose reduction, improved therapeutic algorithms with biologics as well as will have a significant influence on cost reduction of biologics.

Patients presenting with typical manifestations of GPA, MPA and EGPA and testing positive for antineutrophil cytoplasmic antibodies (ANCA) are readily diagnosed and successfully treated using currently accepted protocols. Less typical presentations may be difficult to identify and include ANCA negative GPA, ENT limited GPA, MPA with asynchronous organ involvement and systemically ill asthmatic patients without obvious vasculitic manifestations. An accurate diagnosis will lead to appropriate treatment and a favorable outcome.

Pediatric rheumatologists often have a number of patients with autoinflammatory conditions. However, adult rheumatologists who see pediatric rheumatology patients often have much less opportunity during their training to become familiar with these often complex conditions with highly variable presentations, overlapping features, and key medications needed for their successful treatment. For adult rheumatologists who care only for adults, these children grow up to be adults who continue to have auto-inflammatory diseases that are relatively much more rare in adult populations than in pediatric populations. Additional familiarity with the types and typical presentations of patients with auto inflammatory conditions can be very important in properly recognizing, diagnosing and treating these patients as adults.

More than 20 experimental agents have failed to meet the primary endpoint in phase 2 and 3 randomized controlled trials (RCTs) in SLE, yet some, such as cyclophosphamide, mycophenolate mofetil and rituximab, are clearly effective. Belimumab is approved following 3 positive phase 3 RCTs, yet its clinical benefit remains controversial. Promising agents currently in phase 3 trials include anifrolumab, an anti-IFN $\alpha$  receptor mAb, atacicept: an inhibitor of BlyS and APRIL, thereby B cell function and ustekinumab. Why do so many SLE trials fail? Reasons include: trial designs and choices of primary outcome measures; domains of SLE assessment, choice of responder analyses and insufficient emphasis on patient reported outcomes; use of active standard of care; prolonged GC tapering regimens and mandated rescue; heterogeneous patient populations and trial implementation including inclusion criteria, site selection, geographical bias and strict definitions of treatment failure to allow early rescue. Understanding these challenges can better inform interpretation of future RCT data as well as clinical practice.

## EDUCATIONAL OBJECTIVES

- At the conclusion of the RAN 3rd Annual Meeting, attendees will be able to:
1. Describe the current therapeutic targets in the pathogenesis of RA.
  2. Explain the rationale for current strategies to inhibit cytokines in RA.
  3. Recognize the effectiveness of novel monoclonal antibody and small molecule strategies in the treatment of RA.
  4. Explain the strategies in both methotrexate-naive and inadequate responders to withdraw biologics.
  5. Review the data supporting dose reduction of biologics.
  6. Explain the development of biosimilars and recent data supporting their approval and concerns for the clinician.
  7. Describe which characteristics best define an active (responsive) patient population in SLE clinical trials.
  8. Describe the challenges presented by use of active background therapy as the 'placebo control' and the importance of using definitions of "treatment failure".
  9. Describe clinically meaningful outcomes that can assist interpretation of RCT data in SLE.
  10. Identify the common clinical characteristics shared by most auto-inflammatory conditions.
  11. Recognize key distinguishing patterns of lab studies obtained from patients with active auto-inflammatory conditions.
  12. Identify which key medications tend to be most effective for patients with auto-inflammatory conditions.
  13. Recognize when consulting a pediatric rheumatologist may be helpful in diagnosing and treating adults with auto-inflammatory conditions.
  14. Identify less typical presentations of GPA, MPA and EGPA.
  15. List effective treatment options for patients with less typical ANCA-associated vasculitic syndromes.
  16. Describe groups that are most at risk for suicide.
  17. Identify how to assess a patient's risk of committing suicide and what factors can be protective for suicide.
  18. Describe effective means of reducing suicide rates.
  19. Review of psychotropic medications used for suicidal thoughts and the importance of reviewing medication compliance.
  20. Explain signs and symptoms of self harm.

## ACCREDITATION

### SAPS CME ACCREDITATION STATEMENT:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Medical Association of Georgia through the joint providership of the Southern Alliance for Physician Specialties CME and the Rheumatology Association of Nevada. The Southern Alliance for Physician Specialties CME is accredited by the Medical Association of Georgia to provide continuing medical education for physicians.

The Southern Alliance for Physician Specialties CME designates this live activity for a maximum of **5.75 AMA PRA Category 1 Credits™**. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and other healthcare professionals will receive a Certificate of Attendance. For information on the applicability and acceptance of Certificates of Attendance for educational activities certified for *AMA PRA Category 1 Credit™* from organizations accredited by the ACCME, please consult your professional licensing board.

### General Disclaimer

The statements and opinions contained in this program are solely those of the individual authors and contributors and not of the Rheumatology Association of Nevada. The appearance of the advertisements is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. The content of this publication may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses. The Rheumatology Association of Nevada disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the abstracts or advertisements.

### Special Assistance

We encourage participation by all individuals. If you have a disability, advance notification of any special needs will help us better serve you. Call (847) 517-7225 if you require special assistance to fully participate in the meeting.

# PROGRAM

## RHEUMATOLOGY ASSOCIATION OF NEVADA 3RD ANNUAL MEETING

April 27 - 28, 2018  
Hard Rock Hotel & Casino

All sessions will be located in **Revolution AB** unless otherwise noted.  
Speakers and times are subject to change.

### FRIDAY, APRIL 27, 2018

4:30 p.m. - 7:00 p.m. **Registration/Information Desk Hours**  
*Location: Revolution Foyer*

5:30 p.m. - 7:30 p.m. **Exhibit Hall Hours**  
*Location: Graceland*

5:30 p.m. - 7:30 p.m. **Welcome Reception in Exhibit Hall**

### SATURDAY, APRIL 28, 2018

7:30 a.m. - 4:30 p.m. **Registration/Information Desk Hours**  
*Location: Revolution Foyer*

7:30 a.m. - 1:30 p.m. **Exhibit Hall Hours**  
*Location: Graceland*

7:30 a.m. - 8:30 a.m. **Continental Breakfast**  
*Location: Graceland*

8:20 a.m. - 8:30 a.m. **Welcome and Opening Remarks**  
President: Ewa Olech, MD

8:30 a.m. - 9:30 a.m. **KEYNOTE LECTURE: Emerging Novel Therapies in Rheumatoid Arthritis**  
Edward C. Keystone, MD, FRCP(C)  
*Mount Sinai Hospital*

9:30 a.m. - 10:30 a.m. **KEYNOTE LECTURE: Reducing the Cost of Biologics: Dose Reduction, Withdrawal, and Biosimilars**  
Edward C. Keystone, MD, FRCP(C)  
*Mount Sinai Hospital*

10:30 a.m. - 11:00 a.m. **Break and Networking in Exhibit Hall**

11:00 a.m. - 12:00 p.m. **Suicide Prevention**  
Ellen B. McBride, MD

12:00 p.m. - 1:00 p.m. **Industry Satellite Symposium Lunch**  
*Location: Revolution CD*

1:00 p.m. - 1:30 p.m. **Dessert and Networking in Exhibit Hall**

1:30 p.m. - 2:00 p.m. **RAN Annual Business Meeting**

2:00 p.m. - 2:45 p.m. **Managing Psoriatic Arthritis to Improve Patient Outcomes**  
Sudhakar Tumuluri, MD  
*Northern California Rheumatology Society (NCRS)*

2:45 p.m. - 3:30 p.m. **Auto-Inflammatory Conditions in Kids (Who Grow Up to be Adults!)**  
Robert Lowe, MD, PhD  
*Juvenile Arthritis & Rheumatology Care & Research Center*

3:30 p.m. - 4:15 p.m. **Case-Based Review of ANCA-Associated Vasculitis Treatment**  
Lester E. Mertz, MD  
*Mayo Clinic Arizona*

4:15 p.m. - 4:30 p.m. **Q&A Session**

4:30 p.m. **Closing Remarks and Adjournment**

#### Disclaimer Statement

Statements, opinions and results of studies contained in the program are those of the presenters/authors and do not reflect the policy or position of RAN nor does RAN provide any warranty as to their accuracy or reliability.

# FACULTY DISCLOSURES

## FACULTY DISCLOSURE REPORT

Rheumatology Association of Nevada 3rd Annual Meeting  
April 27 - 28, 2018

In accordance with the ACCME Accreditation Criteria, the Southern Alliance for Physician Specialties (SAPS), as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. Therefore, it is mandatory that both the program planning committee and speakers complete disclosure forms. Members of the program committee were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations. The ACCME defines a 'commercial interest' as "any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients". It does not consider providers of clinical service directly to patients to be commercial interests. The ACCME considers "relevant" financial relationships as financial transactions (in any amount) that may create a conflict of interest and occur within the 12 months preceding the time that the individual is being asked to assume a role controlling content of the educational activity.

The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure and to allow the audience to form its own judgments regarding the presentation.

PLANNING COMMITTEE / CME ORGANIZERS	DISCLOSURE		
	Company	Role with Commercial Interest	Nature of Relationship
KELLY, MD, G. Timothy CME Organizer	AbbVie, Amgen	Grants/Research Support	Grants/Research
	AbbVie, Amgen	Honorarium	Speaker
KNOWLES, MD, Susan CME Organizer	Lily, Exagen (AVISE)	Consultant	Consulting Fees
OLECH, MD, Ewa President, CME Organizer	Pfizer	Consultant	Speaker's Bureau
	AbbVie, Amgen, Merck, Pfizer	Other Financial or Material Support	Research
	Bristol Meyers Squibb	Grants/Research Support	Consultant
YUNG, MD, Christianne CME Organizer	Mallinckrodt	Consultant	Consultant
	GlaxoSmithKline	Grants/Research Support	Research

SPEAKERS / MODERATORS / PANELISTS / DISCUSSANTS / CO-AUTHORS	DISCLOSURE		
	Company	Role with Commercial Interest	Nature of Relationship
KEYSTONE, MD, FRCP(C), Edward Speaker	Abbott, Amgen, AstraZeneca, Bristol-Myers Squibb, F. Hoffmann-LaRoche, Janssen, Lilly, Novartis, Pfizer, Sanofi-Aventis	Grants/Research Support	Research
	Amgen, Abbott Laboratories, Bristol-Myers Squibb Canada, F. Hoffmann-La Roche Inc., Janssen Inc., Merck, Pfizer Pharmaceuticals, Sanofi Genzyme UCB	Honorarium	Speaker
	Abbott Laboratories, AstraZeneca Pharma, Biotest, Bristol-Myers Squibb Company, Celltrion, Crescendo Bioscience, F. Hoffmann-La Roche Inc, Genentech Inc, Gilead, Janssen Inc, Lilly Pharmaceuticals, Merck, Pfizer Pharmaceuticals, UCB, Sandoz	Consultant	Consultant

# FACULTY DISCLOSURES

## FACULTY DISCLOSURE REPORT (continued)

Rheumatology Association of Nevada 3rd Annual Meeting  
April 27 - 28, 2018

SPEAKERS / MODERATORS / PANELISTS / DISCUSSANTS / CO-AUTHORS	DISCLOSURE		
	Company	Role with Commercial Interest	Nature of Relationship
LOWE, MD, PhD, Robert Speaker	Nothing to disclose		
MCBRIDE, MD, Ellen Speaker	Nothing to disclose		
MERTZ, MD, Lester Speaker	Nothing to disclose		
OLECH, MD, Ewa President, CME Organizer	Pfizer	Consultant	Consultant
	Abbvie, Amgen, Merck, Pfizer	Other Financial or Material Support	Speaker's Bureau
	Bristol Meyers Squibb	Grants/Research Support	Research
TUMULURI, MD, Sudhakar Speaker	Novartis, Celgene, Janssen, Genentech, Sanofi, Horizon, Myriad	Honorarium	Speaker

# BIOSKETCHES

## Edward C. Keystone, MD, FRCP(C)

Dr. Keystone obtained his Doctorate of Medicine degree from the University of Toronto in 1969. After a further five years of training in Rheumatology, he received his specialty degrees (or fellowships) in Rheumatology and Internal Medicine in 1974. He then carried out his research training at the Clinical Research Centre in Harrow, London, UK until 1976. He was on staff as a consultant rheumatologist at The Wellesley Central Hospital, Toronto, Canada from 1976 to 1998 before taking up his current position at Mount Sinai Hospital.

Dr. Keystone is a professor of Medicine at the University of Toronto. He is a Senior Consultant in Rheumatology at Mount Sinai Hospital. In 2003 Dr. Keystone established The Rebecca Macdonald Centre for Arthritis and Autoimmune Disease - a centre devoted to research of genomics, therapeutics, and outcomes in autoimmune inflammatory joint disease. He is Director of the Centre and heads the Advanced Therapeutics Division which focuses on novel therapeutics in Rheumatoid Arthritis. Dr. Keystone is a consultant to the pharmaceutical and biotechnology industry, and is a member of numerous national and international biopharmaceutical advisory boards.

Dr. Keystone is also involved in outcome and translational research studies in Rheumatoid Arthritis. He is the author of over 300 peer-reviewed papers and more than 100 book chapters, reviews and invited papers. He has been the recipient of numerous honours, including the Senior Investigator Award of the Canadian Rheumatology Association and the American College of Rheumatology's Grand Master Award in 2008. Dr. Keystone also received a Lifetime Excellence in Rheumatology Teaching Award at the Rheumatology Winter Clinical Symposium Conference in January 2011 well as the Congress of Clinical Rheumatology Outstanding Speaker Award in the spring of 2011. In 2012, Dr. Keystone was chosen an "Alumni of Influence" by the University College of The University of Toronto, Canada. In 2014 he was awarded "Rheumatologist of the Year, by the Ontario Rheumatology Association.

## Robert Lowe, MD, PhD

Dr. Lowe is a board certified pediatric rheumatologist and enjoys caring for kids with arthritis, lupus, and many other pediatric rheumatologic conditions. He is also a physician scientist and has performed research in the areas of the genetics and epigenetics of lupus in kids. He is dedicated to improving our understanding of how lupus develops in kids and helping develop new, more effective treatments for kids with autoimmune diseases.

Dr. Lowe's first venture into basic research was as a pre-doctoral fellow working with Dr. Michael Blaese at the NIH exploring gene therapy for cytosine deaminase deficiency. Later, Dr. Lowe received his MD and his PhD in Cellular & Molecular Biology from the University of Washington, where he studied HLA and CTLA-4 polymorphism associations with autoimmune diabetes. During his Pediatric Rheumatology fellowship at Case Western Reserve University, Dr. Lowe explored mesenchymal stem cell therapy in a murine arthritis model.

Dr. Lowe is the Founder and Director of the Kids Arthritis Care - Juvenile Arthritis and Rheumatology Care and Research Center, the only dedicated pediatric rheumatology clinic in the state of Nevada. The clinic is focused solely on providing the best medical care in the country for children with juvenile arthritis, lupus, mixed connective tissue disease, vasculitis, Sjogren's syndrome, periodic fever syndromes, and many other rheumatologic conditions that affect children. Prior to coming to Las Vegas, Dr. Lowe served for five years on the faculty of the University of Alabama at Birmingham.

## Ellen B. McBride, MD

Dr. McBride grew up in rural Wisconsin and began college at the University of Minnesota. After growing weary of the Minnesota winters with some days reaching 30 below zero she decided to move to a warmer climate. She fell in love with Reno after experiencing 50 degree weather while visiting a friend December 1979. And moved to Reno the following month. Initially pursued a degree in Accounting but found it rather dull. Returned to UNR and took prerequisites for medicine. Dr. McBride graduated from University of Nevada School of Medicine in 1995 and completed a residency in Psychiatry. Currently Dr. McBride works at West Hills Hospital and maintains a private practice in Reno, NV.

## Lester E. Mertz, MD

Dr. Mertz is an Assistant Professor of Medicine at the Mayo Clinic School of Graduate Medical Education, Rheumatology Division, Department of Internal Medicine. She is also the Rheumatology Division Education Coordinator. Dr. Mertz received her medical degree from the Medical College of Wisconsin in 1981 and completed her residency at the Medical College of Wisconsin in 1984. She then completed her fellowship in 1987 at the Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine.

From 1987 to 1997, Dr. Mertz was chair of the Division of Rheumatology at the Mayo Clinic, Department of Internal Medicine. She became chair again from 2004 to 2015. Dr. Mertz is currently a member of the American College of Rheumatology, the American Medical Association, and the Maricopa County Medical Society.

## Ewa Olech, MD

Dr. Olech is president of the Rheumatology Association of Nevada. She is board-certified in rheumatology and has a private practice at Access Health in Las Vegas, NV. She is also a Medical Director at QuintilesIMS and an Adjunct Faculty at the UNLV. Prior to that, Dr. Olech was an Associate Professor of Medicine, Chief of Rheumatology, and Research Director at the University of Nevada School of Medicine.

Dr. Olech has extensive experience in clinical rheumatology and was named Top Doctor by Vegas Seven Magazine and Castle Connolly Medical, Ltd in 2014, 2015, 2016, and 2017. Her disease of interest is rheumatoid arthritis and she is particularly interested in musculoskeletal imaging. She has authored many publications and presented on numerous occasions on these topics. Dr. Olech has 15 years of experience in clinical research studying efficacy and safety of new biologic therapies for the treatment of rheumatoid arthritis. She also has experience in conducting clinical trials in systemic lupus erythematosus, lupus nephritis, Sjogren's syndrome, osteoarthritis and osteoporosis.

Dr. Olech is one of the Founding Members of the International Society for Musculoskeletal Imaging in Rheumatology, where she currently serves as Treasurer. Additionally, Olech has recently been elected to serve on the Board of Directors panel of the Intersocietal Accreditation Commission MRI. She is a fellow of the American College of Rheumatology.

## Sudhakar, Tumuluri, MD

Dr. Tumuluri is a Rheumatologist in private practice in the Bay Area, with offices in San Francisco and Redwood City. He grew up in Indiana and completed his undergraduate studies at the University of Pennsylvania. Returning home for medical school, Dr. Tumuluri graduated from the IU School of Medicine in 1995. He then completed 3 years of Orthopedic Surgery Residency, but in 1998, against the wishes of his father (a private practice hand surgeon), he made the switch to Internal Medicine and eventually completed a fellowship in Rheumatology all at Case Western University Hospitals in Cleveland, Ohio.

SANOFI GENZYME




***REGENERON***

**welcome you!**

Visit our booth

Sanofi Genzyme and Regeneron are committed to providing resources to better understand the pathogenesis of rheumatoid arthritis and to research the unmet needs of patients with this disease.

# EXHIBIT HALL FLOOR PLAN



**WORKING  
TOGETHER  
FOR *Patients***<sup>™</sup>

**At Bristol-Myers Squibb, we are  
working together for patients**

Our mission is clear — we discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our sense of urgency is real — we work every day to push the boundaries of scientific discovery and to make a meaningful difference in the lives of patients. **It's what we do. It's why we do it.**

**Bristol-Myers Squibb is proud to support the 2018  
Rheumatology Association of Nevada Conference**



**Bristol-Myers Squibb**

[bms.com](http://bms.com)

© 2018 Bristol-Myers Squibb Company.

# EXHIBIT HALL FLOOR PLAN

Company Name	Table #	Company Name	Table #
AbbVie	10	Janssen Biotech	6
Alexion Pharmaceuticals	2	Lilly	19, 20
Altus Infusion	9	Mallinckrodt Pharmaceuticals	11
Amgen	8	McKesson Specialty Health	1
Antares Pharma	7	Medac Pharma	14
Bristol-Myers Squibb	23	Novartis	26
Celgene	21	Pfizer	25
Crescendo Bioscience	4	Pfizer Biosimilars	16
Exagen Diagnostics	15	Radius Health	13
Genentech	27, 28	Sanofi Genzyme Regeneron	24
GlaxoSmithKline	17, 18	TSI Healthcare	22
Horizon Pharma	3	UCB, Inc	12
IntraFUSION	5		
Arthritis Foundation, Amgen Scientific Education, CSRO - FOYER			

**taltz**<sup>®</sup>  
(ixekizumab)  
injection  
80 mg/mL

**COME FOR  
THE DATA  
STAY FOR THE  
RESULTS**

**MEET TALTZ  
AT BOOTH LOCATION**

Learn about the Taltz Savings Card Program at [taltz.com/hcp](http://taltz.com/hcp)

If you are a US medical doctor with an active state license number, the value of the food, beverage, and/or educational item that you receive when attending this program may be disclosed on Eli Lilly and Company's Physician Payment Registry and/or the National Physician Payment Transparency Program (NPPTP) Open Payments report under the federal Sunshine Act as a transfer of value made to you by Lilly. As a result of enacted state regulations, food and beverages will not be provided to healthcare professionals licensed in the states of Minnesota, Massachusetts, and Vermont. Additionally, educational items will not be provided to healthcare professionals licensed in Minnesota. Federal Veterans Affairs (VA) regulations and several states also prohibit state/government employees from receiving or being provided gift items, which may include educational materials and meals. Please consult your state regulations and ethics laws to see if such prohibition would apply to you. This medical presentation is intended only for invited healthcare professionals for whom the information to be presented is relevant to their practice. We regret that spouses or other guests cannot be accommodated. This is a promotional program and no continuing medical education (CME) credits are offered.

Taltz is a registered trademark of Eli Lilly and Company. PP-IX-US-1020 11/2016 ©2016, LILLY USA, LLC. ALL RIGHTS RESERVED. PRINTED IN USA ON POST-CONSUMER RECYCLED PAPER ♻️

*Lilly*

# INDUSTRY SYMPOSIA

## INDUSTRY SPONSORED SYMPOSIUM EVENT

SATURDAY, APRIL 28, 2018

12:00 p.m. - 1:00 p.m.

---

### Industry Satellite Symposium Lunch

*Location: Revolution CD*

Sponsored by: Bristol-Myers Squibb

**“Do you really know Orencia?”**

Dr. Frank Welbourne

# GENERAL MEETING INFORMATION

## REGISTRATION/INFORMATION DESK HOURS

*Location: Revolution Foyer*

Friday, April 27, 2018      4:30 p.m. - 7:00 p.m.

Saturday, April 28, 2018      7:30 a.m. - 4:30 p.m.

## EXHIBIT HALL HOURS

*Location: Graceland*

Friday, April 27, 2018      5:30 p.m. - 7:30 p.m.

Saturday, April 28, 2018      7:30 a.m. - 1:30 p.m.

# THANK YOU TO OUR SUPPORTERS

## THANK YOU TO OUR 2018 PROMOTIONAL PARTNERS


### GOLD LEVEL PARTNER

---



### SILVER LEVEL PARTNERS

---



## THANK YOU TO OUR 2018 CONTRIBUTOR

Bristol-Myers Squibb

## THANK YOU TO OUR 2018 EXHIBITORS

AbbVie	IntraFUSION
Alexion Pharmaceuticals	Janssen Biotech, Inc.
Altus Infusion	Lilly
Amgen	Mallinckrodt Pharmaceuticals
Amgen Scientific Education	McKesson Specialty Health
Antares Pharma	Medac Pharma, Inc.
Arthritis Foundation	Novartis
Bristol-Myers Squibb	Pfizer Biosimilars
Celgene Corporation	Pfizer, Inc.
Crescendo Bioscience, Inc.	Radius Health
Exagen Diagnostics, Inc.	Sanofi Genzyme Regeneron
Genentech	TSI Healthcare
GlaxoSmithKline	UCB, Inc.
Horizon Pharma, Inc.	







SAVE THE DATE  
Rheumatology Association of Nevada  
RAN 4TH ANNUAL MEETING  
APRIL 26 - 27, 2019  
Las Vegas, Nevada



---

**RHEUMATOLOGY ASSOCIATION OF NEVADA**

1100 E Woodfield Road, Suite 350  
Schaumburg, IL 60173  
P: (847) 517-7225 | F: (847) 517-7229  
[ran@wjweiser.com](mailto:ran@wjweiser.com)

---